Cialis, Levitra market share numbers
Executive Summary
Lilly/Icos' erectile dysfunction therapy Cialis is tracking approximately three percentage points ahead of Bayer/GlaxoSmithKline's Levitra, Lilly said. Lilly reported that for the week ending March 12, Cialis (tadalafil) captured 18.1% of new prescriptions while Levitra (vardenafil) held a 15.4% share. Bayer reported new Rx market share of 16% during its year-end investor meeting March 18 (1"The Pink Sheet" March 22, 2004, p. 27). Both agents are in a head-to-head battle to overtake Pfizer's Viagra, which remains the market leader...
You may also be interested in...
Pfizer Viagra “Value Card” Offers Buy-Six-Get-One-Free Script Deal
Pfizer's Viagra "Value Card" offers patients a free prescription of the erectile dysfunction disorder drug after every six they buy
Bayer/GSK Levitra Has 16% Share Of New Scripts; 2003 Sales Reach $180 Mil.
Bayer/GlaxoSmithKline's Levitra has a 16% share of new prescriptions in the erectile dysfunction disorder market, Bayer CFO Klaus Kuhn reported during a year-end investor meeting March 18
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.